An observational study in Syncope Recurrent, Syncope, Vasovagal, Neurally-Mediated and Cardioneuroabaltion, sponsored by Fundación de investigación HM. Recruiting at 27 sites in Spain. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Fundación de investigación HM · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Spanish multicenter registry of cardioneuroablation (ablation of cardiac ganglionated plexi) in patients with reflex syncope and functional bradyarrhythmias Background Cardioneuroablation (CNA) is the catheter ablation of the ganglionated plexi (GP) of the intrinsic cardiac autonomic nervous system, located in the atrial epicardial fat, to reduce parasympathetic tone on the sinus node and the atrioventricular (AV) node. It has been proposed as an alternative to pacemaker implantation in patients, often young, with cardioinhibitory reflex syncope or vagally mediated bradyarrhythmias. However, the available evidence comes mainly from single-center series at highly experienced centers, with heterogeneous techniques (choice of atrium, number of GP targeted, localization method, type of anesthesia) and no standardized acute procedural endpoint. Data from real-world clinical practice are needed to define its efficacy and safety, and to identify which patients and which procedural strategies are associated with better outcomes.
Objectives Primary: to assess syncope recurrence after CNA in real-world clinical practice in Spain.
Secondary: 1) to describe the procedural characteristics and complications of CNA; 2) to identify clinical and procedural predictors of success; 3) to evaluate the change in syncope and presyncope burden and the need for pacemaker implantation during follow-up.
Design Observational, multicenter, ambispective, ongoing registry with 27 participating hospitals in Spain. Cases performed since June 2018 are collected retrospectively, and prospective enrollment of consecutive patients has been in place since April 2021.
Study population
Inclusion criteria: consecutive patients undergoing CNA for syncope with one of the following phenotypes:
CNA is performed according to the usual practice of each center. The operator chooses:
Endpoints Primary endpoint: first syncope recurrence after CNA. Secondary endpoints: procedure-related complications; number of syncopal and presyncopal episodes per year before and after CNA; pacemaker implantation during follow-up.
Ongoing sub-studies:
89 studies on the registry are indexed under Syncope, Vasovagal; 29 are open to participants now.
This study's planned enrollment of 400 is above the median of 140 across 30 observational studies indexed under Syncope, Vasovagal.
Browse Syncope, Vasovagal studies →Fundación de investigación HM is the lead sponsor of 23 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients treated with cardioneuroablation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
cardioneuroablation
syncope
recurrence of syncope
Time frame: From the procedure (cardioneurobation) to short-term follow up (3 months) and long term follow up (one-year recurrence, 2- year, 3-year and 4-year recurrence)
Complications
Complications
Time frame: During procedure and 3 months after
Plan to share: Undecided
Started Jun 2018 (actual). Primary completion is estimated for Dec 2030, 150 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación de investigación HM